Global Cardiac Biomarkers Testing Market Size By Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I)), By Application (Myocardial Infarction, Congestive Heart Failure), By Region, And...

The Global Cardiac Biomarkers Testing Market was valued at USD 9.4 billion in 2023 and is projected to reach USD 18.7 billion by 2031, expanding at a CAGR of 8.9% during the forecast period from 2023 to 2031. Cardiac biomarkers play a vital role in the early diagnosis, risk stratification, and management of cardiovascular diseases (CVDs), including myocardial infarction and acute coronary syndromes. The increasing global burden of cardiovascular diseases, rising awareness regarding early detection, and the growing use of point-of-care (POC) testing are key drivers supporting the rapid expansion of this market.

Drivers

1. Rising Prevalence of Cardiovascular Diseases:

Cardiovascular conditions remain the leading cause of death globally, creating a significant need for effective diagnostic tools. Cardiac biomarkers enable rapid identification of cardiac events, which is crucial for timely treatment.

2. Advancements in Biomarker Testing Technologies:

Innovations in assay sensitivity, multiplexing capabilities, and integration with digital health tools are driving the demand for high-precision, rapid diagnostic solutions.

3. Growth in Point-of-Care Testing:

The shift toward decentralized testing through portable and easy-to-use POC devices has greatly expanded access to cardiac diagnostics, especially in emergency and rural settings.

Restraints

1. High Costs of Advanced Biomarker Assays:

Despite their benefits, the cost of novel biomarker tests can limit their adoption in resource-constrained healthcare systems and low-income countries.

2. Regulatory Challenges and Standardization Issues:

Inconsistencies in biomarker standardization and varied regulatory requirements across regions can hinder market expansion and product approval timelines.

Opportunities

1. Integration with AI and Big Data Analytics:

AI-powered analysis of biomarker data is paving the way for predictive diagnostics and personalized treatment strategies, unlocking new market potential.

2. Expanding Healthcare Infrastructure in Emerging Economies:

Rising healthcare investments and diagnostic awareness in countries like India, Brazil, and Indonesia offer lucrative growth opportunities for cardiac biomarker test providers.

3. Increasing Adoption in Preventive Health Programs:

Governments and health organizations are increasingly incorporating cardiac biomarker testing into routine health checks, bolstering long-term market prospects.

Market by System Type Insights

Based on system type, the Lab-Based Testing segment dominated the market in 2023 due to its high accuracy and established infrastructure in hospitals and diagnostic centers. However, the Point-of-Care Testing segment is expected to witness the fastest growth during the forecast period, fueled by the need for rapid diagnosis in emergency settings and increasing availability of portable testing devices.

Market by End-use Insights

In terms of end-use, Hospitals held the largest market share in 2023, owing to the comprehensive diagnostic capabilities, skilled personnel, and high patient footfall. The Ambulatory Surgical Centers (ASCs) and Homecare Settings segments are also gaining traction due to the rising trend of home-based testing and early intervention approaches.

Market by Regional Insights

North America led the global cardiac biomarkers testing market in 2023, driven by advanced healthcare infrastructure, high prevalence of cardiac conditions, and proactive health monitoring practices. Asia-Pacific is projected to exhibit the highest CAGR during the forecast period due to expanding access to healthcare, increased investments, and heightened awareness of heart health in countries such as China and India.

Competitive Scenario

Key market players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, bioMérieux, Danaher Corporation, Thermo Fisher Scientific, Quidel Corporation, Becton Dickinson & Company, and Randox Laboratories. These companies are focusing on expanding their product portfolios through new product launches, strategic collaborations, and technological innovations.

Key Market Developments:

March 2023: Abbott Laboratories received FDA approval for a new high-sensitivity troponin assay designed to improve diagnostic precision in emergency departments.

July 2024: Roche Diagnostics launched a next-generation cardiac biomarker panel using AI-assisted data interpretation.

January 2025: Siemens Healthineers partnered with a cloud analytics platform to deliver real-time data integration for cardiac diagnostics in hospital settings.

Scope of Work – Global Cardiac Biomarkers Testing Market

Report Metric Details

Market Size (2023) USD 9.4 billion

Projected Market Size (2031) USD 18.7 billion

CAGR (2023–2031) 8.9%

Market Segments By System Type (Lab-Based, Point-of-Care); By End-Use (Hospitals, ASCs, Homecare); By Region

Growth Drivers Rise in cardiovascular diseases, advancement in diagnostic technology, increase in POC adoption

Opportunities AI integration, growth in emerging markets, preventive care expansion

FAQs

1) What is the current market size of the Global Cardiac Biomarkers Testing Market?

The market was valued at USD 9.4 billion in 2023.

2) What is the major growth driver of the Global Cardiac Biomarkers Testing Market?

The major driver is the increasing prevalence of cardiovascular diseases and the growing demand for early and rapid diagnosis.

3) Which is the largest region during the forecast period in the Global Cardiac Biomarkers Testing Market?

North America remains the largest regional market, while Asia-Pacific is expected to witness the highest growth rate.

4) Which segment accounted for the largest market share in the Global Cardiac Biomarkers Testing Market?

The Lab-Based Testing segment held the largest share in 2023.

5) Who are the key market players in the Global Cardiac Biomarkers Testing Market?

Major players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific.